Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Agios Pharmaceuticals reported revenue of $54M in the fiscal year ended Dec 2025, up 48.0% from the year before. Operating income was −$472M, an operating margin of −873.9%, and net income was −$413M. Operating cash flow of −$373M less capital expenditure of $4M left free cash flow of −$377M.
Ranks among the 82 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 14.2 | 26.8 | 36.5 | 54.0 |
| Cost of revenue | 0.0 | 1.7 | 2.9 | 4.2 | 6.3 |
| Gross profit | 0.0 | 12.5 | 23.9 | 32.3 | 47.7 |
| Research & development | 257 | 280 | 296 | 301 | 340 |
| Selling, general & admin | 121 | 122 | 120 | 157 | 180 |
| Operating income | −378 | −389 | −391 | −426 | −472 |
| Pre-tax income | −357 | −232 | −352 | 718 | −414 |
| Income tax | – | 0.0 | 0.0 | 44.2 | −1.0 |
| Net income | 1,605 | −232 | −352 | 674 | −413 |
| Diluted EPS | 26.55 | −4.23 | −6.33 | 11.64 | −7.12 |
| Diluted shares | 60.4 | 54.8 | 55.7 | 57.9 | 58.0 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 203 | 139 | 88.2 | 76.2 | 89.1 |
| Receivables | 4.4 | 0.0 | – | – | – |
| Inventory | 0.0 | 8.5 | 19.1 | 27.6 | 32.9 |
| Current assets | 1,064 | 833 | 834 | 966 | 942 |
| Net PP&E | 28.9 | 23.0 | 15.4 | 11.7 | 10.8 |
| Total assets | 1,438 | 1,239 | 937 | 1,663 | 1,297 |
| Payables | 16.7 | 18.6 | 9.8 | 16.6 | 18.4 |
| Deferred revenue | 0.0 | – | – | – | – |
| Current liabilities | 59.8 | 62.6 | 68.0 | 81.2 | 82.2 |
| Total liabilities | 146 | 138 | 126 | 122 | 104 |
| Shareholders' equity | 1,292 | 1,101 | 811 | 1,541 | 1,193 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −407 | −309 | −296 | −390 | −373 |
| Capital expenditure | 5.7 | 4.9 | 1.0 | 1.7 | 4.3 |
| Free cash flow | −413 | −314 | −297 | −392 | −377 |
| Depreciation & amortisation | 8.8 | 8.4 | 6.6 | 5.7 | 5.2 |
| Stock-based compensation | 53.5 | 49.3 | 44.8 | 42.8 | 52.6 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | – | 88.4% | 36.1% | 48.0% |
| EPS growth (YoY) | – | −115.9% | – | – | −161.2% |
| Gross margin | – | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating margin | – | −2732.1% | −1459.5% | −1166.5% | −873.9% |
| Net margin | – | −1627.8% | −1312.6% | 1845.9% | −764.0% |
| Return on equityBlank when equity is negative | 124.2% | −21.1% | −43.4% | 43.7% | −34.6% |
| ROCEEBIT ÷ (assets − current liabilities) | −27.5% | −33.1% | −45.0% | −26.9% | −38.9% |
| Free cash flow margin | – | −2207.6% | −1107.5% | −1072.7% | −698.3% |
| Cash conversion (CFO ÷ net income) | −0.25x | 1.34x | 0.84x | −0.58x | 0.90x |
| Receivable days | – | 0 | – | – | – |
| Inventory days | – | 1819 | 2417 | 2420 | 1894 |
| Payable days | – | 3988 | 1239 | 1459 | 1056 |
| Current ratio | 17.8x | 13.3x | 12.3x | 11.9x | 11.5x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.